After concerns on safety triggered a pause, AstraZeneca has resumed clinical trial of it’s vaccine . AstraZeneca Plc and the University of Oxford have resumed the British clinical trials of its Covid-19 vaccine, after the initial suspension over concerns with a participant who fell ill. University of Oxford, in a statement, said that the UK regulator, Medicines Health Regulatory Authority (MHRA), had recommended a restart of the trials, after an independent review of the safety data triggered a pause on September 6. It revealed some 18,000 people have received ‘study vaccines’ as part of the trials, but declined to disclose any details about the participant’s illness, for confidentiality reasons. AstraZeneca Plc said, “The UK committee has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume. The statements from both AstraZeneca Plc and the University of Oxford did not make any disclosure about the status of tests outside the UK lthough...
Comments
Post a Comment